Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis

Abstract

Cerebrotendinous xanthomatosis (CTX) is a rare disorder due to defective sterol 27-hydroxylase causing a lack of chenodeoxycholic acid (CDCA) production and high plasma cholestanol levels. Our objective was to review the diagnosis and treatment results in 43 CTX cases. We conducted a careful review of the diagnosis, laboratory values, treatment, and clinical course in 43 CTX cases. The mean age at diagnosis was 32years; the average follow-up was 8years. Cases had the following conditions: 53% chronic diarrhea, 74% cognitive impairment, 70% premature cataracts, 77% tendon xanthomas, 81% neurologic disease, and 7% premature cardiovascular disease. The mean serum cholesterol concentration was 190mg/dL; the mean plasma cholestanol level was 32mg/L (normal <5.0mg/L), which decreased to 6.0mg/L (-81%) with CDCA therapy generally given as 250mg orally 3 times daily. Of those tested on treatment, 63% achieved cholestanol levels of <5.0mg/L; 91% had normal liver enzyme levels; none had significant liver problems after dose adjustment. Treatment improved symptoms in 57% at follow-up, but 20% with advanced disease continued to deteriorate. In the United States, CDCA has been approved for gallstone dissolution, but not for CTX despite long-term efficacy and safety data. Health care providers seeing young patients with tendon xanthomas and relatively normal cholesterol levels, especially those with cataracts and learning problems, should consider the diagnosis of CTX so they can receive treatment. CDCA should receive regulatory approval to facilitate therapy for the prevention of the complications of the disease.